MicroRNA-765 (miR-765)

MicroRNA-765 (miR-765) is a short single-stranded non-coding RNA molecule that primarily functions as a post-transcriptional regulator of gene expression by binding to target mRNAs and inhibiting their translation or promoting their degradation. MiR-765 is implicated in a range of cancers where it exhibits either tumor-suppressor or oncogenic functions depending on the cell type and disease context. In clear cell renal cell carcinoma and breast cancer, miR-765 acts as a tumor suppressor, inhibiting cell proliferation, migration, and invasion by targeting oncogenes such as PLP2 and EZH1. Conversely, in multiple myeloma, miR-765 can serve an oncogenic role by directly targeting and downregulating SOX6. Plasma levels of miR-765 may be used as a diagnostic and prognostic biomarker for cancer detection and monitoring. The molecule is also regulated by estrogen receptor beta (ERβ) signaling in response to drugs like fulvestrant in prostate cancer cells. Therapeutic approaches targeting miR-765 require careful consideration of its complex, context-dependent activities and potential challenges in achieving specificity and safe delivery[1][2][3][4][5][6].

Other names

hsa-miR-765MIR765hsa-mir-765MIRN765mir-765

MicroRNA-765 functions as a tumor suppressor by downregulating oncogenic targets (e.g., PLP2, EZH1, EMP3, SOX6). It negatively regulates EZH1 expression in breast cancer and PLP2 in renal cell carcinoma. Its mechanism involves direct binding to target mRNAs, leading to their degradation or translation inhibition.